A Phase II trial from the German–Austrian AML Study Group (AMLSG 16-10) evaluated midostaurin with induction chemotherapy followed by alloSCT and one year of midostaurin maintenance therapy in a cohort of 440 patients with newly diagnosed FLT3-ITD positive AML [62]. Here, FLT3 is linked to acute myeloid leukemia.